ActivePhase 2Phase 3ACTRN12607000181404

Efficacy of Memantine [N- Methyl- D- Aspartate (NMDA) receptor antagonist] versus placebo in acute non arteritic anterior ischemic optic neuropathy (NAION)

In patients with NAION (Non-arteritic anterior ischemic optic neuropathy), is Memantine as good as or better than placebo for improving visual functions?

Sponsor

Tehran University of Medical sciences

Enrollment

44 participants

Start Date

Jun 1, 2006

Study Type

Interventional

Conditions

Non arteritic anterior ischemic optic neuropathy (NAION)

Summary

Evaluation of the neuroprotective effect of Memantine in visual function of patients with acute NAION. Our hypothesis was that Memantine helps for better improvement of visual function in acute phase of NAION

Eligibility

Sex: Both males and femalesMin Age: 40 Yearss

Plain Language Summary

Simplified for easier understanding

This study tests the effectiveness of memantine, a medication that works on brain receptors, for treating a neurological or cognitive condition. This study is open to both men and women aged 40 and older. Participation involves taking memantine or a placebo and attending regular check-ups to monitor your symptoms.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

intervention: Memantine tablets for treatment group for 3 weeks orally(5mg/day for the first week and 10 mg/ day for the next two weeks)

Locations(1)

Iran, Islamic Republic Of

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000181404